Format

Send to

Choose Destination
Diabetes. 2019 Jul;68(7):1366-1379. doi: 10.2337/db19-0119.

Standardizing T-Cell Biomarkers in Type 1 Diabetes: Challenges and Recent Advances.

Author information

1
Immunotherapies Program, Research, JDRF, New York, NY.
2
Benaroya Research Institute at Virginia Mason, Seattle, WA.
3
St Vincent's Institute of Medical Research, Victoria, Australia.
4
Departments of Pediatrics and Integrated Immunology, Barbara Davis Center for Diabetes, University of Colorado, Aurora, CO.
5
Department of Immunobiology, King's College London, London, U.K.
6
Department of Diabetes Immunobiology, City of Hope Diabetes & Metabolism Research Institute, Duarte, CA.
7
Departments of Immunobiology and Medicine, Yale School of Medicine, New Haven, CT.
8
Department of Pathology, University of Florida Diabetes Institute, Gainesville, FL tbrusko@ufl.edu.

Abstract

Type 1 diabetes (T1D) results from the progressive destruction of pancreatic β-cells in a process mediated primarily by T lymphocytes. The T1D research community has made dramatic progress in understanding the genetic basis of the disease as well as in the development of standardized autoantibody assays that inform both disease risk and progression. Despite these advances, there remains a paucity of robust and accepted biomarkers that can effectively inform on the activity of T cells during the natural history of the disease or in response to treatment. In this article, we discuss biomarker development and validation efforts for evaluation of T-cell responses in patients with and at risk for T1D as well as emerging technologies. It is expected that with systematic planning and execution of a well-conceived biomarker development pipeline, T-cell-related biomarkers would rapidly accelerate disease progression monitoring efforts and the evaluation of intervention therapies in T1D.

PMID:
31221801
PMCID:
PMC6609980
[Available on 2020-07-01]
DOI:
10.2337/db19-0119

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center